Physician

Mark R Wieland, MD

According to 2025 Medicare claims, Mark Wieland, MD (NPI: 1134114382) practices ophthalmology in the San Jose-Sunnyvale-Santa Clara, CA market, with the plurality of this provider's patient population coming from Santa Clara, CA. This provider's primary affiliated billing organization is NORTHERN CALIFORNIA RETINA VITREOUS ASSOCIATES MEDICAL GROUP, INC. (NPI: 1538275920; TIN: 942906234) and primary practice location at 95124-4002.

Wieland's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,340 traditional Medicare patients, billed 70,905 HCPCS/CPT codes, and received $3,617,523 in Medicare payments. The top billing code was 92014 (Established patient complete exam of visual system). Part D data shows 119 prescription claims across 31 beneficiaries totaling $10,171 in drug costs, led by Latanoprost (Latanoprost). Open Payments data shows 23 records totaling $79,512. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,451,355 to $3,617,523. In contrast, Part D prescription costs have fallen sharply in recent years, from $38,687 to $10,171. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.8M$3.6M2015 Medicare payment: $1,451,355 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,557,451 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,624,797 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,213,327 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,814,320 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,923,353 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $3,266,148 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $3,080,144 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $3,099,095 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,617,523 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,20713,415$1,451,355
20161,20113,090$1,557,451
20171,21412,212$1,624,797
20181,28114,769$2,213,327
20191,32416,345$2,814,320
20201,11214,288$2,923,353
20211,23015,270$3,266,148
20221,20515,304$3,080,144
20231,22130,075$3,099,095
20241,34070,905$3,617,523

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$31K$61K2015 Drug cost: $38,687 (USD; Tot_Drug_Cst)2016 Drug cost: $59,289 (USD; Tot_Drug_Cst)2017 Drug cost: $50,294 (USD; Tot_Drug_Cst)2018 Drug cost: $61,014 (USD; Tot_Drug_Cst)2019 Drug cost: $48,079 (USD; Tot_Drug_Cst)2020 Drug cost: $43,876 (USD; Tot_Drug_Cst)2021 Drug cost: $42,214 (USD; Tot_Drug_Cst)2022 Drug cost: $35,131 (USD; Tot_Drug_Cst)2023 Drug cost: $17,805 (USD; Tot_Drug_Cst)2024 Drug cost: $10,171 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015133374$38,687
2016136414$59,289
2017131373$50,294
2018132386$61,014
2019112393$48,079
202089282$43,876
202180257$42,214
202254230$35,131
202341188$17,805
202431119$10,171

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
92014Established patient complete exam of visual system9411,389$113
67028Injection of drug into eye3891,887$109
92012Established patient problem focused exam of visual system4701,620$89
92134Imaging of retina1,2353,436$40
J2777Injection, faricimab-svoa, 0.1 mg20958,620$27

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
LatanoprostLatanoprost312,349$571
Timolol MaleateTimolol Maleate251,260$383
Ketorolac TromethamineKetorolac Tromethamine11623$71

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.8$338Genentech USA, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.15$79,175Genentech, Inc.
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Mark R. Wieland, MD?

Tedicare shows public-source Medicare data for Mark R. Wieland, MD (NPI 1134114382), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark R. Wieland, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark R. Wieland, MD?

Mark R. Wieland, MD is linked to NORTHERN CALIFORNIA RETINA VITREOUS ASSOCIATES MEDICAL GROUP, INC. (billing NPI 1538275920) in the available physician profile data.

Does Mark R. Wieland, MD have Open Payments data?

Mark R. Wieland, MD has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.